ClinicalTrials.gg
RecruitingNCT06456502Updated Jun 13, 2024

Effectiveness of Non-invasive Neuromodulation in Patients With Long-COVID

An interventional study of Non-invasive neuromodulation and Placebo in Long-COVID and Post-acute COVID-19 Syndrome, sponsored by Universidad Rey Juan Carlos. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-13.

Sponsored by Universidad Rey Juan Carlos · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 52 studies in Post-Acute COVID-19 Syndrome with a site in Spain — 13 open to participants now, 16 under way, 1 of them phase 3. Post-Acute COVID-19 Syndrome · Spain.

Planned enrollment
28th of 39
44 · median 60
Started
2024
with 2 others
No phase
31 of 52
7 open now
Primary completion
2026-06
later than 8 of 15 live
Registered
36th of 52
by date
Lead sponsor
2 of 52
Universidad Rey Juan Carlos

Among the 52 studies in Post-Acute COVID-19 Syndrome with a site in Spain, this one is the 28th largest by planned enrollment of the 39 interventional ones that give a count, is one of 3 that started in 2024, is one of 31 with no phase, reaches primary completion later than 8 of the 15 other live ones, and was the 36th registered.

Post-Acute COVID-19 Syndrome

606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.

Browse Post-Acute COVID-19 Syndrome studies →

Open to participants now

13 of the 52 studies in Post-Acute COVID-19 Syndrome with a site in Spain are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 144 Post-Acute COVID-19 Syndrome studies recruiting now, 69 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Post-Acute COVID-19 Syndrome with a site in Spain, or all of them as a file.
02

Study summary

Sleep quality and duration are critical to cognitive, emotional and physical well-being, and poor sleep quality has been associated with an increased risk of cognitive, psychological and cardiometabolic disorders. Several important physiological activities occur during sleep including a reduction in heart rate and blood pressure. In addition, sleep exerts important modulatory effects on hormone release. Previous studies have shown that lack of sleep can generate exaggerated cortisol responses or psychological and physiological stressors. Cortisol has widespread effects throughout the body and brain, affecting mood, arousal, energy, metabolic processes, and immune and inflammatory system functioning. Therefore, disruptions in cortisol secretion during the night can influence a wide variety of processes in our body that may contribute to the perception of poorer sleep quality. In addition, the salivary enzyme α-amylase is considered a biomarker of cognitive, psychosocial, emotional or physical stress. It is important to note that the autonomic nervous system (ANS) regulates several physiological processes, including heart rate, blood pressure, respiration, and digestion. The ANS consists primarily of the sympathetic system and the parasympathetic system. Increased parasympathetic activity is considered to promote health, whereas a dominant or overactive sympathetic branch is considered to be detrimental to health.

A recent study found that both sleep quality and quantity of sleep were associated with resting ANS functioning. They found that poorer sleep quality was associated with greater sympathetic dominance. Research on the sympathetic and parasympathetic branches of the ANS has shown that autonomic imbalances are precursors to disease formation and other health-related risks. Coronavirus disease 2019 (COVID-19), has in many cases involved the presence of long-lasting symptoms several weeks or months after surviving acute infection with the virus, leading to a new disease called long COVID-19 or post-COVID-19 syndrome (PCS). A recent study showed that sleep quality influences the relationship between symptoms associated with sensitization and mood disorders with health-related quality of life in people suffering from long COVID.

Non-invasive neuromodulation directed to ANS may be an option to treat the sleep disorders observed in patients with long COVID.

OBJETIVES:

Therefore, the primary objective of this study is to evaluate the efficacy of a treatment protocol on the ANS by means of non-invasive neuromodulation in aspects related to sleep in long COVID patients compared to placebo. As secondary objectives, we propose to evaluate the efficacy of a treatment protocol on the ANS by non-invasive neuromodulation in aspects related to ANS functioning, psychological variables, fatigue, pain perception and quality of life in patients with long COVID.

03

Conditions studied

  • Long-COVID
  • Post-acute COVID-19 Syndrome

Keywords

  • Post acute COVID-19 syndrome
  • Long-COVID
  • Non-invasive neuromodulation
  • Sleep quality
  • Depression
  • Anxiety
  • Fatigue
  • Quality of life
  • Pain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with long COVID or post- acute COVID syndrome
  • With a evolution of at least 6 months after acute SARS-cov-2 infection
  • Whit symptoms present at baseline.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy.
  • Pacemakers
  • Ulcerations or wounds in the area of electrode application.
  • Decompensated heart disease.
  • Epilepsy and/or choreic syndromes.
  • Frequent medication with , hypnotics or supplements such as melatonin, Ashwagandha or phosphatidylserine.
  • on hands and feet that influence the use of the gloves and socks from the neuromodulation system.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
44 participants (estimated)

Study arms

  • Experimental
    Non-invasive neuromodulation

    The real treatment group using non-invasive neuromodulation

    Device: Non-invasive neuromodulation

  • Placebo comparator
    PLACEBO

    The placebo treatment group (simulation of non-invasive neuromodulation application).

    Other: Placebo

Interventions

  • DeviceNon-invasive neuromodulation

    The treatment plan of non- invasive neuromodulation will be applied for two months, with a frequency of 2 weekly sessions of one hour duration, until completing a total of 15 sessions for each patient. The sessions will always be applied in the same time slot of the day (to avoid influence on the measurements, specially cortisol).

  • OtherPlacebo

    The treatment plan of placebo will be applied for two months, with a frequency of 2 weekly sessions of one hour duration, until completing a total of 15 sessions for each patient. Participants will be attached to the neuromodulation machine, however, the cable will not be connected. Participants will not be able to see the machine connections. The sessions will always be applied in the same time slot of the day (to avoid influence on the measurements, specially cortisol).

06

What researchers measure

Primary outcomes

  1. Sleep quality

    The aspects of sleep to be assessed by means of the Pittsburgh sleep quality index (PSQI) scale and the sleep diary to be completed each morning and handed in on the last day of treatment.

    Time frame: Baseline, at the of 15th session, at 6 month an at one year

Secondary outcomes

  1. Heart variability

    Through the We Cardio device, which provides variables such as resting heart rate (HRV) and the root mean square difference of successive interval between two successive R-waves (RMSSD), which reflects beat-to-beat variation in heart rate and is the main time-domain measure used to estimate vagal (parasympathetic) changes reflected in HRV.

    Time frame: Baseline and at 8 weeks

  2. Cortisol and alpha amylase levels

    Cortisol and alpha amylase levels will be assessed with salivary tests that will be analyzed using a Soma cube reader device.

    Time frame: Baseline and at 8 weeks

  3. Psychological variables

    Depression and anxiety will be evaluated by means of the hospital anxiety and depression scale (HADS) validated in spanish and with a high level of reliability and sensitivity for these variables

    Time frame: Baseline, at 8 weeks, at 6 month an at one year

  4. The quality of life

    This variable will be evaluated by means of the EuroQol 5D (EQ-5D). It is a standardized instrument developed to describe and assess health-related quality of life (HRQoL)

    Time frame: Baseline, at 8 weeks, at 6 month an at one year

  5. Disability

    The impact of the disease on patients will be assessed using the severe acute respiratory syndrome (SARS) functional impairment checklist (FIC), which is a questionnaire that assesses physical and psychological symptoms, as well as disability-related domains. The FIC has been shown to be valid, to show good reliability and to exhibit good psychometric properties for use as a tool to assess physical symptoms and disability-related domains in patients with SARS and patients with persistent COVID.

    Time frame: Baseline, at 8 weeks, at 6 month an at one year

  6. Pain intensity

    Pain will be assessed by means of a numeric pain rating scale (NPRS), which allows measuring the intensity of pain described by the patient with maximum reproducibility between observers.

    Time frame: Baseline, at 8 weeks, at 6 month an at one year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2024; primary completion for Jun 2026, 24 months later.

Of 232 non-industry interventional studies with no phase under Post-Acute COVID-19 Syndrome, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 28. This study's planned 24 months is above that.

Counting every sponsor, half of 243 studies reached it within 16 months; a quarter within 7 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2024
First posted
Jun 13, 2024
StartEst.
Jun 2024
Primary completionEst.
Jun 30, 2026
CompletionEst.
Jun 30, 2026
Last update
Jun 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06456502
Responsible party
Stella María Fuensalida Novo (Proffesor, Universidad Rey Juan Carlos) — Principal investigator
First posted
Jun 13, 2024
Start date
Jun 2024 (estimated)
Primary completion
Jun 30, 2026 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
Jun 13, 2024

Study contacts

Stella Fuensalida Novo, PhD
Contact
stella.fuensalida@urjc.es
+34914884865
Stella Fuensalida Novo, PhD
principal investigator · Universidad Rey Juan Carlos

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion